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Rho A versus Rho C: Localization, role in invadopodia 
formation and invasion of astrocytoma cells 
Saleh B. AL Dimassi 
 
ABSTRACT 
Malignant astrocytomas are associated with high mortality rates; these tumors are 
highly invasive into adjacent areas of the normal brain. It has been established that Rho 
family of GTPases play a central role in regulation of cell migration and invasion. The 
Rho family is ras-related, consisting of the Rho, Rac, and CDC42 subfamilies. The 
Rho Protein has subtypes designated as RhoA, RhoB, RhoC, RhoD, RhoE, and 
RhoH genes. In this study we aim to look at the role both Rho A and Rho C play in 
protrusion formation where we found that upon RhoA knockdown protrusions are no 
longer formed, using 2D time lapse microscopy that shows the depletion of RhoA 
and RhoC leads to the decrease in 2D motility, RhoA knockdown decreases adhesion 
of cells in contrast RhoC knockdown increases adhesion of astrocytoma, and FRET 
based biosensors. In addition to study the role both proteins play in invadopodia 
formation which is not RhoA dependent according to our data, and cellular invasion 
where our results shows an increase in cell invasion upon both RhoA and RhoC 
knockdown. This study examines for the first time, the differential roles of RhoA and 
RhoC isoforms in astrocytoma motility and invasion. 
 
Keywords: RhoA, RhoC, Invadopodia, Invasion, Fret, motility. 
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Chapter1 
Literature Review 
 
1.1Cancer Hallmarks: 
Cancer is a complex group of diseases. It is caused by several factors that are 
divided into extrinsic factors such as tobacco, viruses and radiation, and intrinsic 
factors such as hereditary gene mutations. Coupling of these factors will increase the 
risk of cancer (American Cancer Society, 2014). 
 Cancer cells develop tumors by a series of mutations that occur in critical sites of 
the genome, more specifically in oncogenes and tumor suppressor genes (Al Dimassi, 
Abou Antoun, & El sibai, 2014). These cells have certain characteristics that 
differentiate them from normal cells such as uncontrolled growth, escape from 
growth suppressors, activation and increase in cell motility and invasion, promotion 
of angiogenesis, and inhibition of apoptosis (Hanahan & Weinberg, 2011). 
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Fig. 1. Several mutations must occur in the cell genome to develop cancer. 
Mutation in normal cells (light gray) result in an increase in proliferation rate.  
Mutated cells (light blue) these cells and because of their faster growth of normal 
cells may undergo more mutations resulting in a faster growth, when enough 
mutation is accumulated formation of tumor (blue cells), more mutations need to 
occur to convert this tumor to malignant (red cells) and even to metastatic one to 
reach other organs. (Source: Jay D. Hunt, LSU Health Sciences Center) 
 
1.2.Cancer statistics: 
 
Cancer is considered as one of the leading causes of deaths worldwide. Every year 
around 13 million new cases of cancer are reported (Baskar, Lee, Yeo & Yeoh, 
2012). 
According to the American cancer society, a total of 1,660,290 new cancer cases 
for both sexes will be reported in United States by the end of 2013. Unfortunately 
one third of these cases will die, with an estimated 580,350 deaths by the end of 
same year (Siegel, Naishadham & Jemal, 2013). Based on National Cancer Institute 
an average of 1600 patient will die per day because of cancer in 2013 (American 
Cancer society, 2013). 
An approximate of 40, 000 brain tumor cases were reported between 1973 and 
2001. Half of the cases were diagnosed and confirmed as glioblastoma multiform 
(Deorah, Lynch, Sibenaller & Ryken, 2006). 
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1.3.Brain Cancer: 
1.3.1.Glioblastomas and Astrocytomas:  
 
According to the world health organization, malignant tumors are classified into 
four different grades, from I to IV, where I has the lower aggressiveness with an 
increasing aggressiveness to reach the most with grade IV (Collins, 2004). 
 
 Brain tumors become more malignant with time and are classified into 4 different 
grades, including  (grade II) astrocytomas with an occurrence peak above 25 years of 
age, anaplastic astrosytomas  (grade III), and the most aggressive type glioblastomas 
(grade IV) with occurrences peak above 45 years of age (Biernat, Tohma, 
Yonekawa, Klehihues & Ohgaki, 1997; Deimling, et al., 1993). Survival rate of 
patients with brain tumors differs depending on the aggressiveness and the grade of 
the tumor. For example patients with grade II astrocytomas may survive up to 7 
years, as for patients with grade III anaplastic astrocytomas survive up to 3 to 4 
years. Grade IV is the most aggressive and lethal type of brain tumor, with a survival 
period of less than 1 year (McCormack, Miller, Budzilovich, Voorhees & Ransohoff, 
1992; Simpson, et al., 1993). It’s reported that around 9000 new cases of 
giloblastoma are diagnosed every year in the States (Perry, et al., 2012). This tumor 
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is outlined histologically by cellular atypical, necrotic foci with peripheral cellular 
pseudopalisading, and microvascular hyperplasia. These features differentiate this 
high grade of brain tumor from lower grade astorsyomas (Tso, et al., 2006). 
 
 
1.3.2.Diagnosis: 
Brain tumors represent an overwhelming and unsolved clinical problem despite 
the remarkable advancements in therapies of other types of cancer (Koo, et al., 
2006). Several methods are used to diagnose brain tumors such as biopsy, CT scan, 
PET, ultrasound and MRI. These recent imaging techniques do not determine the 
definite tumor size due to the presence of edema around the tumor site. This makes it 
hard to exactly define the boundaries of the tumor and thus to quantify it (Nimsky, 
Ganslandt, Kober, Buchfelder, & Fahlbusch, 2001). 
 
 
1.3.3.Treatment: 
Brain tumors are basically treated via surgery followed by chemotherapy, 
radiation therapy and photodynamic therapy (Ullrich & Pomeroy, 2003). Each of 
these treatments has limiting factors, Surgery is very invasive to the brain: it is in fact   
impossible to remove the tumor mass without destroying brain tissues and causing 
damage. In addition, it is difficult to remove the whole tumor mass without leaving 
some of the cancerous cells in the site (Albayrak, Samdani & Black, 2004). The 
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remaining three types of therapies are considered as non-invasive (Armstrong, et al., 
2002). Chemotherapy is not selective and can affect both normal and cancerous cells, 
in addition to the development of multidrug resistance system in cancer cells 
resulting in the rejection of the drug by tumor cells (Gatmaitain & Arias, 1993). 
Unlike chemotherapy, radiation therapy targets narrower and more specific areas of 
the tumor. Unfortunately tumor develops resistant mechanisms resulting in tumor 
recurrence, cell survival and inhibition of apoptosis (Begg, Stewart & Vens, 2011). 
 
1.3.4.Brain cancer and Invasion: 
Glioblastoma invades the surrounding brain sites. This type of invasion is highly 
reliant on growth factors and signaling pathways that regulate cell motility (Demuth, 
et al., 2000). The highly invasive type of the glioblastoma leads to the failure of the 
treatments used to target this cancer (Giese, Bjerkvig, Berens & Westpal , 2003). 
Glioblastoma cells invade as single cells; their invasion is either through white 
matter of the brain or through blood vessel walls and subpial glial space. Grade IV 
gliomas do not metastasize outside the brain, unless they are the result of other 
cancer cells that have translocated to the brain and formed a secondary tumor   
(Bellail, Hunter, Brat, Tan & Van Meiret, 2004). 
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1.4.Cell migration and invasion: 
1.4.1.Cell motility: 
Cell motility is a complicated process that is tightly coordinated by the cell with 
the help of various proteins. These proteins serve to determine the direction of cell 
movement, and to carry out the motility cycle. This cycle is driven and affected by 
actin polymerization and reorganization (Ananthakrishnan & Ehrlicher, 2007).  
 
Cell movement plays a central role in tumor progression resulting in cancer 
spreading and invasion of other organs (Lauffenburger & Horwitz, 1996). The cell 
will first detect a chemoattractant and determine the direction of movement, the cell 
will then extend a protrusion towards the signal (Bailly, Condeelis & Segall, 1998). 
The next step is the stabilization of this protrusion by adhesion to the substratum 
resulting in the anchorage of this protrusion, which allows the cell to pull it self 
towards the stimulus direction. In the mean time the adhesion structures at the rear 
site of the cell start to disassemble resulting in the retraction of the cell tail and 
shifting of the cell position (Ananthakrishna & Ehrlicher, 2007; Condeelis, et al., 
2001). 
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Fig. 2.  2D motility is a multistep process. The first step is formation of protrusion 
(1), followed by anchorage of this protrusion due to the formation of focal adhesions 
(2), then cell contract (3) using the previously formed anchorage resulting in cell 
movement after the disassembly of the focal adhesions at the tail end (step 4 
)(Ladoux & Nicolas, 2012). 
 
1.4.2.Patterns of cells movement: 
 
 Single cells acting individually or by a group of cells can achieve 2D cell 
motility. Single cell migration is described above. In multiple cell movement, as  is 
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the case in tumors, a leading cell forms a track by proteolytic activity leading to the 
degradation of the extracellular matrix, then the other cells in the group follow the 
leader resulting in increased proteolysis and widening of the previous track formed 
by the leading cell, causing enablement of multiple cells movement. The third pattern 
is collective migration where a group of cells acts a single mega cell (Fried & 
Alexander, 2011). 
 During cancer metastasis, cells migrate on a single cell basis or as a group of 
cells migrating. Single cell movement can be either of amoeboid or mesenchymal 
type. Both types lack cell-cell junctions. On the other hand, multicellular streaming 
follows the same type of movement as single cell migration, except the fact that in 
this case, cell-cell junctions are required for the efficient migration. (Friedl & 
Alexander, 2011). 
 
Fig. 3. Different patterns of cancer cell movement. Individual cell migration 
(amoeboid: leukemia and mesenchymal: stromal tumors) does not need any kind of 
cell cell junctions, as for multicellular streaming were some adhesions are needed as 
fibroblast leading tumors, as for the collective cell migration cell-cell junctions is 
highly required as in differentiated epithelial tumors (Friedl & Alexander, 2011). 
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1.4.3.Invasion /3D motility: 
 Invasion is an essential step of cancer progression and secondary tumor 
formation, by which cancer cells decide to attack and colonize nearby tissues and 
organs. It is believed that cancer cell invasion is a major cause behind the failure of 
treatment of many tumor types (De Wever & Mareel, 2003). In the seed and soil 
theory, Stephan Paget suggested that the cancer cell “seed” depends on the 
competency of secondary cancer site or organ “soil” (Paget, 1889). The site of 
formation of the secondary tumor is not randomly chosen; three types of colonization 
determinations are proposed, the first type is selective growth type where the cancer 
cells grow in organs and tissues that have the growth factors they need. The second 
type is selective adhesion to specific sites and locations at specific organ. The last 
type is selective chemotaxis were the secondary proposed cancer site secretes and 
produces chemicals and other factors that attract and direct these invading cancer 
cells to them (Bogenrieder & Heryln, 2003). 
During invasion around one million cancerous cells leave the initial tumor and 
enter the circulatory system each day, with less than 0.1% of these cells that succeed 
to develop migration (Fidler, 1970; Mack & Marshall, 2010). Tumor cell invasion 
occurs in several steps including: local invasion of neighboring and adjacent tissue,  
transendothelial movement of cancer cells into blood vessels or intravasation, 
survival of cancer cells in the blood stream, and extravasation followed by invading 
and colonizing the targeted secondary tumor site (Van Zijil, Krupitza & Mikulits , 
2011). 
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Fig. 4.  Invasion is a multistep process. Growth of cells as benign tumors followed 
by invasion of basement membrane into blood (intravasation), travel of cells in blood 
and adhesion to capillary walls, finally extravasation and growth of cancer cells at 
secondary tumor site (Alberts, 2002). 
 
 
 
1.4.4.Invadopodia: 
 
Cancer cells need to degrade the extracellular matrix to be able to invade and 
intravasate and this is achieved by structures called invadopodia (Bravo-Cordero, et 
al., 2011). These protrusions formed and extended vertically to ECM are enriched 
with actin regulatory proteins (Condeelis, Singer & Segall, 2005); Polymerization of 
actin is necessary for maturation and formation of invadopodia (Oser, et al., 2009). 
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Invadopodia contain variable proteins that serve different functions such as adhesion 
molecules and matrix degradation proteases (Condeelis,Singer & Segall, 2005).  
 
Fig. 5. Tumor cell invasive types.  The three types are Plasma membrane blebs, 
invadopodia or pseudopodia. Protruding blebs totally lack actin, invadopodia are rich 
in actin and proteins that regulates actin, as for pseudopodia that depend on Wave 
protein to nucleate actin (Nürnberg,Kitzing & Grosse, 2011). 
 
Invadopodia formation is divided into four stages. Primary gathering of cortactin 
and actin is the first step, which is known as invadopodia initiation. The same 
happens in second step. As for the third stage, the invadopodia maturation step MT1-
MMP is accumulated and matrix degradation is observed. The final step is known as 
late invadopodia stage that is characterized by presence of MT1-MMP and matrix 
degradation with the absence of actin and cortactin (DesMarais, et al., 2009). 
 
 
! "#!
1.5.Rho GTPases: 
 RAS protein superfamily includes different protein sub families as Ras, Rab, 
ARf, Rho, and Ran families. The Rho family is characterized by the presence of Rho 
domain. Rho family of GTPases contains 20 members that are divided into 8 
different subfamilies (Boureux,Vignal, Faure & Fort, 2007). These proteins, which  
vary in size between 20 KDa and 40 KDa, are considered as key players and 
regulators of cancer cell migration and invasion (Boettner & Van Aelst, 2002). 
Rho proteins act as molecular switches. They cycle between two states, the active 
one that is bound to GTP and the inactive state that is bound to GDP (Jaffe & Hall, 
2005). GEF, GAP, and GDI proteins tightly regulate this switching between the two 
states. Guanine nucleotide exchange factors ”GEFS” promote the activation of Rho 
proteins by facilitating the release of GDP and the binding of GTP, GAPs or GTPase 
activating protein, act opposite to GEFs resulting in the hydrolysis of GTP and the 
deactivation of Rho protein (Bos, Rehmann & Wittinghofer, 2007). As for “GDIs “ 
guanine nucleotide dissociation inhibitors, which can bind both, the GDP bound 
form and the GTP bound form by binding to the C-terminal group, preventing the 
membrane association of GTPases and insulating them in the cytoplasm, thus 
preventing their contact to down stream effector proteins and targets (Etienne-
Manneville & Hall, 2002). 
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Fig. 6. The Activation and deactivation cycle of Rho GTPases. Rho proteins cycle 
between two forms the active one binding GTP that can stimulate down 
stream reactions and inactive form that bound to GDP. Three proteins 
regulates this switching GEF which promotes switching to the active 
form,GAP works opposite to GEF,and the third protein GDI that can hold 
both forms the active and in active one away from their membrane binding 
sites and stoping their function (Aktories & Barbieri, 2005). 
 
1.5.1.Rho A and Rho C: 
 
Rho family consists of three isoforms: Rho A, RhoB and Rho C (Mouneimne, et 
al.,2004).Rho A and Rho C activation is  increased in human tumors (Del Pulgar,  
Benitah, Valeron, Espina & Lacal,2005). 
 
 Studies have shown that Rho A plays a  role in cancer cell proliferation and 
survival .It was found that Rho A promotes  epithelial polarity in addition to junction 
assembly and function(Jaffe & Hall, 2005; Braga & Yap, 2005).  Rho A is important 
for amoeboid and mesnchymal motility. Rho A and Rock cross talk leads to the 
! "#!
promotion of actomyosin dependent contractility resulting in amoeboid migration, in 
addition to the retraction of the tail in mesenchymal migration (Friedl & Wolf, 
2003). 
 
Previous study showed that overexpression or knocking down RhoA will lead to 
the decrease of 2D motility, it also effect the maturation and formation of focal 
adhesions. The same study shows that RhoA is responsible for protrusion formation 
and its localized at the edges of cell, and it undergo activation and deactivation cycle 
(Khalil, et al., 2013) 
 
As for Rho C, its role in cancer is restricted to metastasis. It has been found that 
Rho C is up regulated in metastatic melanoma, whereby several studies correlate Rho 
C with invasion and motility, however the mechanism is still not .The difference 
between Rho C effect and Rho A is also of a lot of interest (Bellovin, et al., 2006; 
Pillé, et al., 2005;Clark, Golub, Lander & Hynes, 2000;Simpson, Dugan & Mercurio, 
2004;Miles, Pruitt, Van Golen & Cooper, 2008). 
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1.1. Purpose of the Study 
 
Our first objective in the current study is to investigate the distinctive roles 
that Rho A and Rho C play in the progression of astrocytomas, by studying how 
how the absence of Rho A and Rho C affect the phenotype and morphology of 
astrocytic cancer cells. The second aim is to determine the roles of these two 
proteins in the regulation of 2D cell motility. We also investigate their effect on 
cell adhesion is considered a crucial and important step of cell invasion.  
In addition we aim to study the different roles they play in invasion or 3D 
motility of astroscytomas, through the formation of invadopodia.This study is the 
first to distinguish between the roles of RhoA and RhoC isoforms in astrocytoma 
motility and invasion. 
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Chapter 2 
 
MATERIALS & METHODS 
 
 
2.1. Cell Culture 
Human astrocytoma cell line SF268 was cultured in DMEM medium 
supplemented with 10% FBS and 100U penicillin/streptomycin at 37°C and 5% 
CO2 in a humidified chamber.  
 
 
2.2. Antibodies and reagents 
Goat polyclonal anti-StarD13 antibody, Mouse monoclonal anti-Actin 
antibody,Rabbit polyclonal anti-Rock1 antibody and Rabbit polyclonal a, anti-
Rock2 antibody were obtained from Santa Cruz Biotechnology. Mouse 
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monoclonal anti-RhoA, mouse monoclonal anti-Rac1, were purchased from 
Upstate biotechnology, Lake Placid, NY. Mouse polyclonal anti-RhoC obtained 
from abcam. Anti-goat, anti- Rabbit and anti-mouse HRP-conjugated secondary 
antibodies were obtained from Promega.  
Fluorescent secondary antibodies (AlexaFluor 488) were obtained from Invitrogen. 
To visualize the actin cytoskeleton, cells were stained with Rhodamine 
phalloidin (Invitrogen).  
 
 
2.3. Cell transfection with siRNA 
Goat FlexiTube siRNA for StarD13, RhoA, RhoC, Rock1, Rock2 and Rac1 were 
obtained from Qiagen. The cells were transfected with the siRNA at a final 
concentration of 10 nM using HiPerfect (Qiagen) as described by the 
manufacturer. Control cells were transfected with siRNA sequences targeting GL2 
Luciferase (Qiagen). After 72 hours, protein levels in total cell lysates were 
analyzed by western blotting using the appropriate antibodies or the effect of the 
corresponding knockdown was assayed. 
 
 
2.4. Cell transfection with vectors 
Cells were transfected with 5 µg dominant active RhoA, or control empty control 
vectors using Lipfectamine LTX with plus reagent (Invitrogen) as described by 
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the manufacturer. Cells were incubated with the transfection complexes for 4 
hours then reefed with DMEM supplied with 30% FBS. The experiments were 
carried on 24 hours following transfection.  
RhoA construct was a generous gift from Dr. Hitoshi Yagisawa from the 
University of Hyogo, Japan and Dr. Hideki Yamaguchi from the Albert Einstein 
College of Medicine, New York, USA.  
The construct was transformed into One Shot TOP10 chemically competent E. 
Coli (Invitrogen), which were grown on a selective medium containing the 
appropriate antibiotic. The vectors were then extracted using Maxi Prep plasmid 
extraction kit from Qiagen. 
 
 
2.5. Western blotting 
Cell lysates were prepared by scraping the cells in a sample buffer  (4% SDS, 10% 
!-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, and 0.125 M Tris-
HCl at a pH of 6.8). The resulting lysates were boiled for 5 minutes. Protein 
samples were separated by SDS-PAGE on 8% (for StarD13) or 15% (for RhoA 
and Rac) gels and transferred to PVDF membranes overnight at 30V. The 
membranes were then blocked with 5% non-fat dry milk in PBS containing 0.1% 
Tween-20 for 1 hour at room temperature and incubated with primary antibody at 
a concentration of 1:100 for 2 hours at room temperature. After the incubation 
with the primary antibody, the membranes were washed and incubated with 
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secondary antibody at a concentration of 1:1000 for 1 hour at room temperature. 
The membranes were then washed, and the bands visualized by treating the 
membranes with western blotting chemiluminescent reagent ECL (GE Healthcare). 
The results were obtained on an X-ray film (Agfa Healthcare). The levels of 
protein expression were compared by densitometry using the ImageJ software.  
 
2.6. Förster Resonance energy transfer (FRET) 
SF268 were transfected with 1 µg of the RhoA fluorescence resonance energy 
transfer (FRET)-based biosensor plasmid. The biosensor consists of (from the N-
terminus) the Rho binding domain (RBD) of the effector Rhotekin, a cyan 
fluorescent protein (CFP), a protease resistant 17-mer unstructured linker, a 
yellow florescent protein (YFP) domain, and a full length RhoA (Pertz, Hodgson, 
Kelmke & Hahan, 2006). FRET image sequences were obtained with an 
automated Olympus IX70 microscope equipped with filter wheels in the excitation 
and emission light path and coupled to a cooled SensiCam QE CCD camera 
(Cooke Corp., MI). CFP was excited using a S430/25 filter with a Sutter DG4 
illuminator (Sutter Instruments, Novato, CA) and the fluorescence detected with a 
S470/30 (donor image) or S535/30 (FRET image) emission filter. YFP was 
imaged with exciter S500/20 and emitter S535/30 (YFP image). In all cases a 
dual-band dichroic mirror 86002v2bs was used (Chroma Technology Corp., VT). 
Images were background corrected and the YFP images were thresholded to 
generate a binary mask with values of 1 within the cell and 0 for the background. 
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The increase in FRET signal due to activation of RhoA was detected by ratioing 
the FRET image (CFP excitation- YFP emission) to the donor image (CFP 
excitation- CFP emission). FRET signals were quantified by averaging the mean 
FRET ratio in regions of interest in cells. For the live FRET movies, the cells were 
transfected with the RhoA biosensor as described above, and images of the cells 
moving randomly in serum were taken at a 1 minute time interval for 1 hour. The 
images from each frame were analyzed as described above.  
 
2.7. Immunostaining 
The cells were plated on cover slips, and the appropriate treatment was applied. 
Cells were fixed with 4% paraformaldehyde for 10 minutes, and permeabilized 
with 0.5% Triton-X100 for 10 minutes. To decrease background fluorescence, 
cells were rinsed with 0.1 M glycine then incubated with 0.1 M glycine for 10 
minutes. For blocking, cells were incubated 4 times with 1% BSA, 1% FBS in 
PBS for 5 minutes. Samples were stained with primary antibodies for 2 hours and 
with fluorophore-conjugated secondary antibodies for 2 hours. Fluorescent images 
were taken using a 60X objective on a fluorescent microscope. 
 
 
 
2.8. Motility assay/Analyzing 2D motility:  
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For motility analysis, images of cells moving randomly in serum were collected 
every 60 seconds for 2 hours using a 20X objective. During imaging, the 
temperature was controlled using a Nikon heating stage which was set at 37 °C. 
The medium was buffered using HEPES and overlayed with mineral oil. The 
speed of cell movement was quantified using the ROI tracker plugin in the ImageJ 
software, which was used to calculate the total distance travelled by individual 
cells. The speed is then calculated by dividing this distance by the time (120 
minutes) and reported in µm/min. The speed of at least 15 cells for each condition 
was calculated. The net distance travelled by the cell was calculated by measuring 
the distance travelled between the first and the last frames.  
2.9. Adhesion assay 
96-well plates were coated with collagen using Collagen Solution, Type I from rat 
tail (Sigma) overnight at 37 °C then washed with washing buffer (0.1% BSA in 
DMEM). The plates were then blocked with 0.5% BSA in DMEM at 37 °C in a 
CO2 incubator for 1 hour. Washing the plates and chilling them on ice followed 
this. Meanwhile, the cells were trypsinized and counted to 4x105 cell/ml. 50 µl of 
cells were added in each well and incubated at 37°C in a CO2 incubator for 30 
minutes. The plates were then shaken and washed 3 times. Cells were then fixed 
with 4% paraformaldehyde at room temperature for 10 minutes, washed, and 
stained with crystal violet (5 mg/ml in 2% ethanol) for 10 minutes. Following the 
staining with crystal violet, the plates were washed extensively with water, and 
left to dry completely. Crystal violet was solubilized by incubating the cells with 
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2% SDS for 30 minutes. The absorption of the plates was read at 550 µm using a 
plate reader.  
 
 
2.10. Boyden Chamber/Invasion Assay: 
Cells were transfected with either control or RhoA siRNAs, RhoC siRNAs,or both 
RhoA and RhoC siRNAs , and the invasion assay was performed 48 h following the 
treatment period using the collagen-based invasion assay (Millipore) according to the 
manufacturer's instructions. Briefly, 24 h prior to the assay, cells were starved with 
serum-free medium. Cells were harvested, centrifuged and then resuspended in 
quenching medium (without serum). Cells were then brought to a concentration of 
1x106 cells/ ml. In the meantime, inserts were prewarmed with 300 µl of serum-free 
medium for 30 min at room temperature. After rehydration, 250 µl of medium was 
removed from the inserts, and 250 µl of cell suspension was added. Inserts were then 
placed in a 24-well plate, and 500 µl of complete medium (with 10% serum) was 
added to the lower wells. Plates were incubated for 24 h at 37˚C in a CO2 incubator. 
Following the incubation period, inserts were stained for 20 min at room temperature 
with 400 µl of cell stain provided with the kit. The stain was then extracted with 
extraction buffer (also provided). The extracted stain (100 µl) was then transferred to a 
96-well plate suitable for colorimetric measurement using a plate reader. Optical 
density was then measured at 560 nm. 
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2.11. Invadopodia formation Assay: 
The cells were plated on cover slips, and the appropriate treatment was applied. Prior 
to staining day cells was starved using L 15 media obtained from gibco with 0.35% 
BSA overnight, then immuno-staining as described before, using rhodamin 
phalloidin targeting actin. Induction of invadopodia was done either by PMA of 
370mM for one hour prior to staining at 37 degrees and 5% CO2. Rock inhibition 
was perforemed-using 30 µM of Rock inhibitor treatment 1 hour at 37 degrees and 
5% CO2 prior to staining. 
! !!
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Fig. 7. The RhoA FRET biosensor. The biosensor consists of (from the N-terminus) 
the Rho binding domain (RBD) of the effector Rhotekin, a cyan fluorescent protein 
(CFP), a protease resistant 17mer unstructured linker, a yellow florescent protein 
(YFP) domain, and a full length RhoA ((Pertz, Hodgson, Kelmke & Hahan, 2006). 
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Chapter 3 
 
RESULTS 
 
!
3.1. RhoA and RhoC Depletion using siRNA 
Before studying the role of RhoA and RhoC in astrocytoma cell motility, 
we first wanted to study the expression level of RhoA and RhoC astrocytoma 
cells before and after the silencing of both proteins genes (Figure 8). 
 
Fig. 8. RhoA and RhoC Depletion. A) Depletion of RhoA after 72 hours of 
transfecting cells with RhoAsiRNA. B) Depletion of RhoC after 72 hours 
transfection and usage RhoCsiRNA .In both experiments actin was used as a loading 
control. 
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3.2. RhoA and RhoC depletion effect on cell morphology 
We started by transfecting cells with siRNAs targeting RhoA and Rho C 
separately, and after 72 hours we look at the morphology of astrocytoma cells in 
response to silencing. RhoA knockdown lead to the loss of cell polarity, 
decrease surface area and elongated, while RhoC knocking down lead to the 
increase in cell surface area and the loss of polarity. (Figure 9).  
 
Fig. 9. Depletion of RhoA or RhoC leads to different changes in cell 
morphology. Representative Phase contrast images of astrocytoma cells 
showing the morphological changes due to RhoA or RhoC knockdown, 
compared to control cells where the expression of these proteins is normal. 
 
 
3.3.RhoA and RhoC are necessary for 2D cell migration 
 
RhoA knock down results in the decrease of cell motility as observed by 
time-lapse microscopy, Same was observed for cells with RhoC knockdown. 
The presence of both proteins is essential for cell migration to occur, 
          Control                                    RhoA Knock down                  RhoC Knockdown 
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quantitation of cell movement was done using image j software where every cell 
was tracked over the 120 frames, 11 cells for each time-lapse movie, and the 
average of the distance was measured    (Figure 10). 
 
 
Fig. 10. RhoA and RhoC positively regulate 2D cell motility. Depletion of RhoA 
or RhoC in astrocytoma cells decreased cell motility as compared to control cells. 
Data are the mean -/+ SEM from 3 different experiments. The results were 
significant with p<0.001. 
 
3.4.RhoA and Rho C play opposite roles in astrocytoma cells adhesion 
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Cells where platted on collagen coated 96 well plates, followed by staining of 
cells by crystal violet and then the absorption of the plates was read at 550 µm 
using a plate reader.  
 RhoC knock down results in increase of cell adhesion, while RhoA 
knockdown decreased the adhesion of astrocytoma cells  (Figure 11). 
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Fig. 11. RhoA and RhoC play different roles in cell adhesion. A) Cells were 
transfected with RhoCsiRNA or luciferase siRNA, and after 72 hours adhesion 
experiments was performed as described in chapter two. B) Cells were transfected 
with RhoA or luciferase siRNA this was followed by adhesion experiment after 72 
hours. Data are the mean -/+ SEM from 3 different adhesion experiments for each 
protein. The results were significant with p<0.01. 
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3.5.RhoA and RhoC depletion promotes 3D invasion in astrocytoma 
After establishing the importance of RhoA and RhoC in cell adhesion, we 
wanted to test their effect in cell invasion as shown in figure 12, this was done by 
knocking down RhoA followed by boyden chamber, where cells invade toward 
rich media with growth factors after being starved and platted in porous inserts, the 
invading cells will be trapped in the pores after that they where stained and 
extracted and measured at 560 nm. Both RhoA and RhoC seem to attenuate cell 
invasion since knocking down either of theses proteins or both led to an increase in 
cell invasion.  
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Fig. 12. RhoA and RhoC have the same effect on cell Invasion. Cells 
were transfected with RhoAsiRNA (A) or with RhoCsiRNA or both (B) and 
tested for invasion. Data are the mean -/+ SEM from 3 experiments. The 
results were significant with p=0.007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
!"#$%"&'
()*+",-*+"!'
()*+"!'
!"
!#$"
%"
%#$"
&"
&#$"
'"
()*+,)-" ./01)(" ./01)2301)("
."
&/
')#
0%
12
(1
')#
')#
32
()"
#'
! "#!
3.6.Invadopodia is not RhoA depenedent 
In response to PMA stimulation, cells produce invadopodia. Starving cells 
in serum free media followed by PMA stimulation and staining the cell with 
rhodamine phalloidin to look at Actin in invadopodia structures. These appeared 
to be completely RhoA independent since knocking down RhoA did not affect the 
formation of invadopodia and no decrease in dots or invadopodia as compared to 
cells expressing RhoA normally  (Figure 13).  
 
A. 
+PMA -PMA 
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Fig. 13. RhoA does not affect invadopodia formation. A) Cells were treated 
with PMA or left untreated and stained with Rhodamine phalloidin. B) Cells were 
transfected with luciferase or RhoAsiRNA, treated with PMA or left untreated 
and stained with rhodamine phalloidin. Data are the mean of +/- SEM of 3 
different experiments .The result were significant with P<0.01. 
 
 
3.7. Invadopodia is not starD13 dependent 
Stard13 is known to be a negative regulator of RhoA, overexpression of 
starD13 leads to the deactivation of RhoA, we wanted to see if stard13 affect 
invadopodia formation. We knocked down stard13 in astrocytoma cells, and then 
we performed invadopodia assay as described before with /without PMA 
stimulation. Invadopodia was formed upon PMA treatment when the cells were 
treated with siRNA for stard13 (Figure 14). 
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Fig. 14. Invadopodia formation doesn’t depend on StarD13. A) Cells were 
transfected with luciferase or stard13siRNA, lysed and blotted using stard13 antibody. 
B) Cells were transfected with siRNA as in (A) treated with PMA or left untreated and 
then stained with rhodamine phalloidin. 
 
 
3.8. Invadopodia is ROCK independent 
Rock is known as down stream effector of RhoA, inhibition of rock using 
the Y26732 rock inhibitor, followed by invadopodia assay and PMA stimulation 
B. 
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revealing the absence of invadopodia. This is consistent with the fact that RhoA 
do not affect invadopodia formation (Figure 15). 
 
 
 
Fig. 15. Invadopodia are rock independent. Cells were transfected by with 
Y27632 as described in chapter two or left untreated, cells were then fixed and 
stained with rhodamine phalloidin. 
 
3.9. Localization of RhoA and its activation 
We used the previously described RhoA biosensor to look and detect the 
localization of RhoA in Glioblastoma cell lines were our finding suggest that RhoA 
is localized at cell edges, in addition to that we examined the activation of RhoA in 
different grades of brain tumor cells that shows different activation ratios depending 
on the grade. This is consistent with the invadopodia. (Figure 16).  
Control Rock Inhibitor Rock I i itor 
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Fig. 16.  Localization and activation of RhoA in brain tumor. A) Using RhoA 
FRET biosensor to detect the localization of RhoA in Brain Tumor cancer cells 
revealed the presence of active form at the edge of cell. B) Activation levels of 
RhoA in different grades of brain tumors. 
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3.10. Invadopodia is RhoC dependent  
 
Upon the depletion of RhoC and PMA stimulation no invadopodia  were 
observed as shown (Figure 17). 
 
Fig. 17. RhoC expression is necessary for invadopodia formation. Cells were 
transfected with luciferase or RhoC siRNA, treated with PMA and or left untreated 
and stained with rhodamine phalloidin.  
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Chapter 4 
 
DISCUSSION 
 
 
 
 
Invasiveness of brain carcinoma and its infiltration to the neighboring locations in 
brain limits the survival of patients from several years to several months, depending 
on the stage of this cancer. Rho Family of GTPases plays a central and important role 
in regulation and controlling cell motility and invasion.  Based on that we wanted to 
determine the effect of the two-rho family members, RhoA and RhoC, on motility 
and invasion of astrocytoma.  
We knocked down the two Rho proteins in astrocytoma cells using specific siRNA 
targeting RhoA and Rho C, and looked at the effect. Cells with low RhoA expression 
or RhoC expression tend to lose their normal shape. RhoA depleted cells lose their 
normal shape and are more extended and elongated. RhoC depletion showed a totally 
opposite phenotype where the surface area of cells is increased and cells look more 
flat than the normal cells. These results suggest that both proteins have different and 
distinctive roles in the regulation of down stream proteins resulting in the difference 
of the two observed phenotypes. The decrease in cell area detected in RhoA 
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knockdown cells suggests that RhoA play a role in stabilizing the protrusion, which 
is consistent with our previous studies done by (Khalil, et al., 2013) and with the 
localization of active RhoA to the cell edge is observed by FRET. The round 
phenotype in RhoC knock down cells is indicative that cells are losing polarity. This 
phenotype is the same as that observed in breast adenocarcinoma upon Rac is overly 
activated (Backer, et al., 2007). Current work in our lab showed that RhoC inhibits 
cdc42. RhoC could be also leading to Rac inhibition through cdc42, which would 
explain why when RhoC is knocked down, the cells mimic a phenotype of an 
increase in active Rac.   
Previous studies showed that RhoA and RhoC play an important role in the 
regulation of cell migration. Therefore, it became of great interest to study the role 
RhoA and RhoC plays in regulating astrocytoma motility. Our data showed that 
depletion of both proteins results in the decrease of cellular motility. These results 
come in accordance to previous studies on prostate cancer (Vega, Fruhwirth & 
Ridley, 2011). Since adhesion is very important and crucial step in cell motility as 
described in chapter one, in addition to our data that shows the change of phenotype 
and decrease in motility upon the knockdown of RhoA and RhoC. The next target 
was to see what would be the effect of both RhoA and RhoC down regulation on 
astrocytoma cell adhesion. Our adhesion data showed a different role RhoA and 
RhoC perform in adhesion control, RhoA depleted cells results in an decrease of 
adhesion while RhoC depleted cells showed the opposite with an increase of 
adhesion. To correlate our findings with each other it is important to keep in mind 
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that cycling of adhesion at different sites of the cell is important to maintain healthy 
migration pattern, RhoA knock down leaded to decrease in 2D motility and with an 
extended phenotype and a decrease of adhesion this suggests that RhoA positively 
regulates adhesion, so once we lose adhesion by knocking down RhoA the cell can 
not adhere any more and thus can not perform efficient movement. On the other hand 
RhoC knockdown resulting in increase of adhesion, which means that the cell is now 
adhered well, and the cycle of formation adhesion structures and this protein 
interrupts the disassembly. This suggests that RhoC in contrary to RhoA negatively 
regulate adhesion. The balance between RhoA and RhoC expression in the cell is 
very important to regulate the adhesion cycling in cell, therefore regulation of cell 
motility. 
After establishing that both RhoA and RhoC positively regulate 2D motility, the 
second part of the study focused on determining both proteins role in 3D motility of 
astrocytoma or invasion.  The invasion results showed that after knocking down 
RhoA invasion increased, the same was observed with RhoC knockdown. This 
finding suggests that both proteins act on the same down stream proteins resulting in 
regulating invasion. In fact RhoC expression increase cellular invasion (Simpson, 
Dugan & Mercurio, 2004) this is contradictory to our RhoC invasion results, as for 
RhoA its role in invasion varies depending on cell type and system (Bellovin, et al., 
2006). The contradiction between our results about the effect of RhoC in invasion 
and other studies in the literature can be explained by the possibility of that RhoC 
effect on invasion is cell and system dependent same as RhoA. 
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As both RhoA and RhoC negatively regulates invasion, the next aim was to study 
their role in the formation on invadopodia. Starting our investigation with knocking 
down stard13 an upstream regulator of RhoA, we found that invadopodia is still 
forming even with the lack of expression of this protein, same goes for RhoA and 
Rock. Our Data suggest that the formation of invadopodia is not RhoA dependent, or 
its upstream regulator stard13, or its down stream effector Rock. Surprisingly after 
knocking down RhoC and even with the presence of PMA no invadopodia was 
observed and formed, this finding leads us to conclude that invadopodia formation is 
RhoC dependent. 
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Chapter 5 
 
CONCLUSIONS 
In this study we tried to point at the distinctive roles that both proteins RhoA and 
RhoC serves in astrocytoma cells invasion, movement and invadopodia formation. 
Our results suggest that RhoA and Rho C expression is necessary for cell movement, 
RhoA expression increases cellular adhesion which is expected as described in 
previous studies done by our lab, the surprising results was when RhoC depletion led 
to the decrease of adhesion, further more both proteins presence decreases cellular 
invasion. Our results also showed that invadopodia formation is RhoA, Rock and 
StarD13 independent, while on the other hand it shows that is RhoC. Fret Results 
suggests that RhoA is localized at the cell edges, where the activation of RhoA is 
increased depending on the grade of brain tumor as the grades increases the 
activation is noticed more. 
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